Navigation Links
ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing
Date:4/8/2009

NORTH BRUNSWICK¿ N.J.¿ April 8 /PRNewswire/ -- ORTHOCON¿ Inc. today announced that Paul R. Sohmer, M.D. has joined the company as President and Chief Executive Officer. The company also announced the closing of a $25 million round of financing led by top-tier healthcare investors.

ORTHOCON is developing innovative implantable devices that deliver therapeutics to bone. The Company's versatile technology platform may be leveraged to deliver a variety of therapeutic agents. ORTHOCON's lead product is a novel extended release local anesthetic bone hemostat designed to stop bleeding and to provide local pain relief. The Company expects to initiate a pivotal clinical trial with this product in the second half of 2009.

"I am thrilled to join the ORTHOCON team," said Dr. Sohmer. "I look forward to working with our management team and our investors to build our Company and to bring an array of novel products to market based on ORTHOCON's innovative platform technology."

ORTHOCON's $25 million financing was co-led by ProQuest Investments and Canaan Partners. The round also included significant participation from ORTHOCON's existing stockholder BB BIOTECH Ventures. Joyce Tsang, Ph.D., General Partner of ProQuest Investments and Dr. Sohmer both joined ORTHOCON's board of directors.

"ORTHOCON is a great late-stage company with the ideal combination of a promising technology platform, a leadership team with a proven track record and great syndicate partners," commented Joyce Tsang, Ph.D. "We believe now is the perfect time to back ORTHOCON and we are delighted to be part of the Company."

"The addition of Paul Sohmer to the team and the strengthening of the finances of the Company through ProQuest joining in this round mark a great milestone for the Company," said ORTHOCON's Chairman and Canaan Partners' board representative, Seth Rudnick, M.D. "With approved products and an advanced
'/>"/>

SOURCE ORTHOCON, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Mylan Announces Clarinex(R) Settlement Agreement
2. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
3. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
4. Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies
5. Shamir Optical Industry Ltd. Announces Receipt of Notice from Nasdaq of Noncompliance with Nasdaq Audit Committee Composition Requirements
6. UnitedLex Announces Strategic Alliance with Oval Ideas to Enable Superior Patent Analytics
7. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
8. Health Career Agents Announces SBA Pre-Approval Program to Launch a Healthcare Recruiting Business
9. M2S Announces Agreement with AG Mednet to Provide Clinical Trial Sponsors with More Options for Efficient Image Transfer and Collection
10. Immucor Announces Fiscal Third Quarter Results
11. IGI Announces Portal Designed to Maximize Data Sharing Between Hospitals and Their Affiliated Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... China (PRWEB) December 22, 2014 Physicians ... MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma (NHL), ... , a leading global healthcare consulting firm. MabThera is ... lymphoma (DLBCL), the most common form of NHL. , ... Access and Barriers,” the incidence of NHL in China ...
(Date:12/22/2014)... Florida (PRWEB) December 22, 2014 Give ... holiday season, the gift of health and vitality. , ... offering its three top-selling anti-aging formulas in special Holiday ... free rush delivery. , Each bottle contains cutting-edge, ... areas that don't work as well as we age. ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... NY (PRWEB) December 22, 2014 ... a 2014 Professional Woman of the Year. She is ... As the largest, most recognized networking organization of professional ... profession, the National Association of Professional Women is a ... 300 Local Chapters. , Ms. Kreider is passionate and ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2
... AHA Create a Unified National Acute Coronary Syndromes ... DALLAS, May 1 The American College of,Cardiology ... Heart Association,s Get With The Guidelines(SM),(GWTG)-Coronary Artery Disease ... create a national unified registry for measuring and,improving ...
... in Product Sales Driven by Robust Growth in Clinical ... ... record revenue of $44.8 million for the first quarter,of fiscal 2008, an increase ... was $1.9 million, or $(0.03) per share, on a,GAAP basis; first quarter net ...
... seed and oil company will focus on new business development ... ULTRA low linolenic, trans fat-free products., ... an,agreement with two key venture capital firms, securing $4 million ... soybean,products. Asoyia is the innovator and leader in developing and ...
... and elsewhere report what is believed to be the ... of heart tissue and the subsequent damage leading to ... findings from the Multiethnic Study of Atherosclerosis (MESA), to ... Journal of the American College of Cardiology, appear to ...
... HILL, N.C., May 1 Leading pharmaceutical,companies ... recruitment,is part of the critical path in ... Trial Excellence: The Science and Art of ... techniques,that speed clinical trial investigator recruitment and ...
... PHILADELPHIA May 1, 2008 Shire plc ... company, announced today that it will present key ... (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and ... extended release, at the American Psychiatric Association (APA) ...
Cached Medicine News:Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 2Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 3Health News:Cepheid Reports Record Revenue of $44.8 Million 2Health News:Cepheid Reports Record Revenue of $44.8 Million 3Health News:Cepheid Reports Record Revenue of $44.8 Million 4Health News:Cepheid Reports Record Revenue of $44.8 Million 5Health News:Cepheid Reports Record Revenue of $44.8 Million 6Health News:Cepheid Reports Record Revenue of $44.8 Million 7Health News:Cepheid Reports Record Revenue of $44.8 Million 8Health News:Cepheid Reports Record Revenue of $44.8 Million 9Health News:Cepheid Reports Record Revenue of $44.8 Million 10Health News:Asoyia Secures Venture Capital Funding 2Health News:Asoyia Secures Venture Capital Funding 3Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Strategies for Winning Clinical Investigators in a Competitive Marketplace 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2
(Date:12/22/2014)... CHESTERBROOK, Pa. and STOCKHOLM ... AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today ... Use (CHMP) of the European Medicines Agency (EMA) has ... (collagenase clostridium histolyticum) for the treatment of adult men ... deformity of at least 30 degrees at the start ...
(Date:12/22/2014)... , Dec. 22, 2014  Pfenex Inc. (NYSE ... recombinant anthrax vaccine, has been filed and is now ... provided by the Department of Health and Human Services ... (BARDA). "We are extremely pleased to have ... Px563L.  This represents a significant milestone in our company,s ...
(Date:12/19/2014)... , December 19, 2014 ... services in the World announced the appointment of ... R. Vonsée, as Chief Channels and Partner Officer. ... since 2004 through to its acquisition by Oracle in ... Director at Geneva and subsequently ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4
... 2011 WaferGen Biosystems, Inc. (OTC Bulletin Board: ... analysis systems, today announced that it has appointed world-renowned ... to its Scientific Advisory Board.   Dr. ... biomarkers in the clinic to choose appropriate therapies for ...
... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) announced ... established a Prescription Drug User Fee Act (PDUFA) date of ... New Drug Application (NDA). The acceptance of the Exelbine NDA ... to permit a substantive review, and the PDUFA date is ...
Cached Medicine Technology:WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 2WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 3WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 4ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 2ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: